RxIntel · Insights
Pharma intelligence, clearly written
Analysis on GLP-1 therapies, drug pricing, and India's pharmaceutical market.
Published
Sandoz Files for Generic Tirzepatide — The Clock Starts, Not the Launch
FDA has accepted two Sandoz ANDAs for tirzepatide (Mounjaro/Zepbound). What the filing means, what happens next — patent litigation, 30-month stay, 2036 compound patent — and what India should watch.
India's GLP-1 Market in 2026: Novo Nordisk, Eli Lilly and India's Generic Manufacturers
India's GLP-1 market is evolving into a strategic battleground. How innovators, generic manufacturers, and regulators are competing before and after the patent cliff.
How Semaglutide and GLP-1 Drugs Are Reshaping Obesity and Metabolic Medicine
GLP-1 therapies have moved far beyond diabetes. Analysis of how semaglutide is reshaping obesity pharmacotherapy, cardiovascular medicine, and long-term metabolic care.
Coming Soon
Ozempic vs Wegovy — Same Molecule, Very Different Price
Why indication-based pricing creates a significant cost gap for identical chemistry.
Tirzepatide vs Semaglutide — The GLP-1/GIP Advantage
What the SURPASS trial data means for prescribers and patients in India.
Looking for GLP-1 pricing data and market intelligence?
RxIntel Insights · rxintel.link/insights